Copenhagen, Denmark

ELCC 2023

We invite you to save the date for the European Lung Cancer Congress (ELCC 2023), taking place onsite in Copenhagen, Denmark from 29 March – 1 April 2023 and online through a dedicated virtual platform.

This edition, for the first time, will feature the innovative LIVE Plus format, which will provide  a wealth of opportunities for exchange of ideas among delegates. 

You will have the chance to learn firsthand, about practice challenges and controversies, brainstorm with peers and explore further opportunities to advance your career. And if you are unable to attend, or would rather connect from a distance, we will continue to offer the convenience of an interactive virtual format.

The European Lung Cancer Congress (ELCC 2023) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.

Make sure you are part of this highly interactive meeting and share your expertise with lung cancer specialists from all over the world.

Access the ELCC 2023 programme here:


The European Lung Cancer Congress 2023 will provide insights into the prevention, diagnosis, biology and multi-disciplinary management of thoracic malignancies. Specifically, the Congress will include educational and scientific sessions covering:

  • Prevention, screening and early diagnosis of thoracic tumours;
  • Recent developments on molecular diagnosis and therapeutic classes for lung cancer;
  • New challenges and opportunities with immuno and targeted therapies;
  • The evolving role of multimodality and multidisciplinary decisions in lung cancer;
  • State of the art for NSCLC, SCLC, mesothelioma and mediastinal tumours.

Learning objectives

  • Update your knowledge in the early detection of thoracic malignancies
  • Review the current state-of-the-art systemic management of lung cancer
  • Learn how to best sequence or combine  multimodal therapies in common and rare thoracic tumours
  • Review the emerging contribution of precision medicine, omics technologies and artificial intelligence in the optimal management of patients with cancers of the thorax


ESMO-MORA: The Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.


All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s). The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons. The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.

The ELCC 2023 abstract submission is now open:

Deadline Date and time
  • Abstracts
  • Trial in Progress
  • Intent to submit LBA

 Tuesday 17 January 2023, 21:00 CET

  • Late-breaking abstracts (LBA)

Wednesday 1 March 2023, 21:00 CET